September 15, 2011
Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs
Posted by D. Daniel Sokol
Abe Dunn (DOJ Antitrust Bureau of Economic Analysis) discusses Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs.
ABSTRACT: The pharmaceutical industry is characterized as having substantial investment in R&D and a large number of new product introductions, which poses special problems for price measurement caused by the quality of drug products changing over time. This paper applies recent demand estimation techniques to construct a constant- quality price index for anti-cholesterol drugs. Demand is estimated using a nationally representative sample of individuals over the period 1996 to 2007 that includes detailed information on individual health conditions, demographics, insurance, and prescription drug choices. Although the average price for anti-cholesterol drugs does not change over the sample period, I .nd that the constant-quality price index drops by 22 percent, a pace more in line with our expectations in such a dynamic segment of the industry. This result is robust to a number of alternative assumptions, highlighting the import! ance of controlling for quality in markets with signi.cant innovation. The demand estimates also reveal that the bene.ts from new innovations depend on the health conditions of individuals which may impact quality-adjusted prices for di¤erent populations.
September 15, 2011 | Permalink
TrackBack URL for this entry:
Listed below are links to weblogs that reference Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs :